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1 Introduction 
This paper reports the findings of the Danish case study on public debate, technology 
assessment and governance of xenotransplantation (XTP) conducted for the CIT-PART 
project (www.cit-part.at). The report is based on analysis of a range of different kinds of 
documents (newspaper reports, policy documents, research literature etc.) and 13 qualitative 
interviews conducted with persons engaged in different manners in the debates about XTP 
in Denmark such as scientists, regulators, politicians or technology assessment (TA) 
practitioners. The interviews were carried out in the period between November 2009 and 
September 2010. Furthermore, qualitative data material from an older study on public 
perceptions of biotechnology from 1999/2000 has briefly been revisited. 
Xenotransplantation has experienced only a modest degree of public attention and policy 
activity in Denmark compared to other countries covered by the CIT-PART sample (full 
reports of all country case studies can be found at www.cit-part.at). Most of this activity was 
concentrated in the years 1998-2002. During that time XTP was the object of some attention 
and activities by the institutions in the Danish policy landscape, which are devoted to 
engaging ―the public‘s‖ concerns in regard to new technology in various ways. However, XTP 
was never the topic of any genuine public participatory process or event in Denmark. In 2001 
a non-statutory but de facto moratorium was issued on XTP, which has remained in force 
until now. The moratorium was suggested first by the Central Committee on Research Ethics 
and was later put into force administratively by the Board of Health, but it was never formally 
sanctioned in legislation. Since then, XTP has drawn little public and policy attention, given 
the focus of scientific research and expectations regarding future treatments largely have 
turned towards other technologies, notably those based on stem cell research. No renewed 
public or policy interest seems to be on the horizon in the foreseeable future, but of course 
this may change if new scientific developments should put XTP on the agenda internationally 
again. 
This report seeks to map the trajectory of XTP as an object of scientific research, of public 
debate, of organised technology assessment and of political discussion and regulatory 
intervention. It also focuses on how these different trajectories interacted. More broadly it 
furthermore examines the context in which this played out. This mapping should serve to 
answer the following research question of the work package: 
Why did XTP experience relatively little attention from “the public” as well as the 
established TA system in Denmark in a context which 1) is otherwise very attentive to 
biotechnological innovation and 2) has a comparatively well established tradition of 
public debate and civic participation in the governance of science and technology? 
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This report recounts how XTP was conceived and treated in four different social fields or 
institutional sectors of the Danish society. These are  
 scientific research, 
 media reports/public debate/public perceptions, 
 the ―Technology Assessment (TA) system‖ and  
 the political/policy field. 
Subsequent to this, the report takes a step back and attempts to answer the research 
question through an interpretation of the Danish experience in relation to XPT. It is 
suggested that the lack of public attention can be ascribed to a combination of the fact that 
the technology never had any strong promoters in the Danish context, scientific, commercial 
or otherwise, and the TA activities that did take place were initiated in a rather top-down 
fashion before the technology was mature enough to generate any genuine public 
engagement and/or mobilisation. 
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2 XTP and related research in Denmark 
In Denmark no clinical trials with XTP have been conducted on human beings. Nor have any 
experiments been carried out on larger mammals (Genteknologiudvalget 2002: 71). One of 
the first medical textbooks on XTP was co-authored by a Danish transplantation surgeon, 
Ejvind Kemp (Cooper et al. 1991). Kemp followed the research field intensively and has 
been one of the most vocal proponents of XTP in the Danish context. However, when XTP 
research gained significant momentum in the wake of new possibilities of genetic 
modification of donor animals, and expectations rose that clinical trials were approaching, 
Kemp had retired. He continued to participate in discussions on the technology in various TA 
processes, but as far as the present research has been able to establish, no other scientists 
have shown the same kind of devotion to XTP. Unfortunately, Kemp was not available for an 
interview for the CIT-PART study. 
For a while in the mid-1990s there was some optimism regarding XTP among Danish 
veterinarian researchers and medical doctors, who engaged with this field in response to 
international developments. The ultimate motive was the hope to alleviate the growing organ 
shortage for heart and kidney transplants in particular. This hope generated some research 
activity related to XTP in Denmark, but XTP research never grew to be very important in 
Denmark, neither in medical or commercial terms. 
Denmark has a large agricultural sector and pig framing has traditionally accounted for a 
significant share of the overall economy. To accompany this production, the country has 
developed a comparatively strong knowledge base and veterinarian research capacity on 
pigs in general. As consensus stabilised in the international scientific discussion that pigs 
were the most suitable donor animal for XTP, veterinarian researchers in Denmark saw 
opportunities to apply their competences in the emerging research. This stimulated some 
shared interests and collaboration between veterinarians and medical researchers working in 
transplantation medicine. However, as far as the present research has been able to 
establish, XTP in itself was never the primary concern of most veterinarian researchers. XTP 
was rather seen as a field of research, where their existing knowledge of porcine genomics, 
embryonic development, etc. could be applied in an interesting manner, and which allowed 
them to tap into the new avenues of research funding accompanying the XTP field. However, 
as these sources dried up due to poor results and the withdrawal of the commercial actors 
from this field, so did the interest in XTP from veterinary researchers in Denmark (Interview 
Professor of Veterinarian Embryology). 
At the height of the XTP research activity medical researchers in Denmark worked primarily 
in basic research, which was carried out on mice and rodents at several universities and 
research hospitals. None of these research groups were seriously approaching clinical 
applications. Rodents were considered convenient animals for basic research in terms of 
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costs and reproduction time. However, as it became clear that for clinical purposes, XTP had 
to rely on porcine material, new avenues for interdisciplinary collaboration were opened up. 
In the hope to ensure Danish participation in this development a ―Danish transgenic pig 
study group‖ was formed, involving researchers from several Danish universities. The 
Danish transgenic pig study group tried to raise funds for research on alpha-gal knock-out 
mechanisms in pigs.
1
 The researchers proposed a partnership with a company specialised in 
pig breeding, which was supposed to put their practical expertise and physical facilities at the 
disposal for the breeding of transgenic pigs in a sterile environment. However, the group 
never managed to attract sufficient funding, and gradually the interest in XTP deteriorated 
(BIOSAM 2004: 4). Basic research on Alpha-gal knock-out problems was therefore 
subsequently continued on mice at much lower costs, and the most of the involved 
researchers focussed their attention on other issues, notably cloning and stem cell research, 
which generated both much more research interest and public controversy in Denmark. The 
transgenic pig study group still exists, but is now devoted to other questions (primarily 
examining pigs as ―model animals‖ for medical research), and XTP related research 
activities are all but extinct in a Danish context (ibid.). 
The waning interest can be attributed in part to the developments in the international 
scientific community around the millennium, which gradually moved its attention towards 
stem cell research, in part to more contingent factors in the Danish context. These have to 
do with the fact that XTP research was never fully institutionalised in research groups etc., 
but was mostly carried out by a few committed individuals in transplantation medicine. 
However, when they retired, the field was virtually abandoned and attracted virtually no 
attention from their successors. In short, there was never any sustained scientific interest in 
driving XTP beyond basic research in the Danish context, and the interest dwindled in a 
relatively short time as technical difficulties regarding rejection, combined with growing 
international concerns about the transmission of zoonotic diseases, proved more difficult to 
overcome than initially expected. 
In fact, it seems that research interest in Denmark was already in decline once the first 
regulatory initiatives got under way. The political concerns about XTP thus seem to be driven 
primarily by international developments and were largely decoupled from domestic scientific 
activities. 
                                                     
1
 That is, it was hoped that by inserting a particular human gene into transgenic pigs, the rejection of transplanted 
organs, which normally occur in cross species transplantations, could be avoided. 
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3 XTP in the public imagery and the media 
The concept of a ―public opinion‖ or a ―public sphere‖ observing, discussing and in some 
cases passing judgement on contemporary affairs is not a unitary or well-defined 
phenomenon (Neidhardt 1993). It is therefore a matter of some discussion in the social 
sciences how ―public opinions‖, ―public debate‖ – or whatever term is preferred – is best 
approached and registered (Bauer and Gaskell 2002). Yet, despite such conceptual 
intricacies some concept or image of the public debate cannot be avoided if we want to 
analyse the trajectory of novel technologies, which in some way or another are relevant to or 
attracts the attention of a significant segment of the population in a democratic country. 
In the present case study XTP as a public topic was approached retrospectively via a 
mapping of media coverage. Media coverage provides a convenient way to capture at least 
some of the concerns about particular topics present in the public sphere, and a means to 
track these over time. This is so for two interrelated reasons: Many of these concerns 
originate from media coverage, which provides most of the knowledge contemporary citizens 
hold of the world (Luhmann 1991). And vice versa: the media make their livelihood from 
being sensitive to public concerns. For this reason, it also seems reasonable to assume that 
political decision makers take at least some of their cues on public preferences from the 
mass media. As such, the printed media leaves an impression of public concerns, which is 
still accessible ten years later when the issue of XTP has more or less disappeared from the 
public view. Towards the end of this section a brief look is also cast on two other sources of 
public perceptions of XTP at the time most policy making took place: the EuroBarometer 
surveys on biotechnology conducted in 1996 and 2002 and a focus group study on public 
perceptions on biotechnology conducted in 1999/2000. 
For the present purpose a search was conducted in a database (InfoMedia) containing a 
complete, verbatim collection of all Danish newspapers in nation-wide circulation, regional 
newspapers and selected trade journal. The search covered the period from January 1
st
 
1985 until October 2009. The word ―xenotransplantation‖ returned a total of 108 journalistic 
articles, commentaries and letters to the editor (excluding non-editorial material such as 
birthdays and anniversaries of scientists etc.). Only three occurrences appear before 1996, 
with the very first appearance of the word in 1991 (a letter to the editor stating in a matter of 
fact manner that within 10 years, it will be possible to provide hearts and kidneys from pigs!). 
Figure 1 shows the distribution of the occurrences of XTP in media reports over time. 
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Figure 1 
(Source: Infomedia database, accessed on October 20
th
, 2009) 
As indicated by Figure 1, ―xenotransplantation‖ as an object of media reports experienced 
most of visibility in the years 1999 – 2002, which coincides with most of the TA and policy 
activities in this area. After 2002, the appearance of the word becomes more infrequent 
again. Practically all reports appear in broadsheet papers and very few in the two leading 
tabloids. Practically all articles provide an explanation of the meaning of the word. Using 
alternative search words such as ―pigs organs AND transplantation‖, ―animal organs AND 
transplantation‖ etc. does not add any significant additional articles. In most cases the 
technical term is either used or explained, and it is assessed that no significant number of 
articles pertaining to XTP has been missed. 
All 108 articles have been read through at least once to conduct an initial screening of 
whether they were substantively related to XTP. Many of them make only superficial 
reference to XTP, but are primarily about other topics. It is assessed that XTP is the 
substantive focus (perhaps among several) of about half (55-60) of the articles. These 
articles have been read through more carefully and provide the material of the following 
attempt to extract the most important issues discussed in relation to XTP and the frames 
applied. The approach is by nature interpretive and aims to identify and analyse frames and 
relations without paying initial attention to the question of whether some issues or framings 
are more dominant than others. 
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The following topics were identified through a mapping of how XTP was framed and related 
to other topic. The framings will be elaborated in the following (numbers in brackets indicate 
number of articles classified in each category). Some articles pertain to several issues: 
 Biotechnological progress and the potential of XTP to alleviate organ shortage (30) 
 Technical challenges and physical risks associated with XTP (36) 
 The ethics of XTP (24) 
 Economic interests in relation to XTP (6) 
 The status of Danish research and regulation of XTP (17) 
3.1 Biotechnological progress 
Research into public engagement with modern biotechnology repeatedly indicates that 
biotechnological innovations are a source of excitement and hope as well as concerns and 
fears about novel risks and transgressions of ethical limits (Bauer and Gaskell 2002). This 
ambivalence applies to the reporting on XTP in the Danish press as well, although the fears 
and concerns appear less outspoken than in relation to other biomedical applications, such 
as stem cell research and genetic testing. XTP is presented in most newspaper articles as a 
means to solve a specific problem; the shortage of organs for donation to patient suffering 
from kidney or heart conditions. This shortage is the state of affairs, on which all reporting 
and discussion is premised, and it is presented as an evident and significant challenge for 
health care. Hence, in practically all accounts XTP is framed as a technology with a specific 
and in principle acceptable purpose – to help alleviate suffering in patients. However, in 
addition to its relation to a specific medical capacity problem, XTP is also frequently 
mentioned as one among many applications of a ―brave new world‖ of biotechnology, where 
various interventions at the genetic level are opening up a host of new possibilities for 
different kinds of treatment, which presents society with a host of challenges. As such, XTP 
is associated with the wider debates around modern biotechnology, including some of its 
more controversial aspects. 
Although framed as a future technology, many accounts – whether primarily supportive or 
critical in their framing – seem to assume that XTP is likely to become reality in a 
―foreseeable‖ though not quite predictable future. Therefore, reporting raises various issues 
affiliated to the – more or less inevitable – introduction of XTP. In doing so general progress 
in genetic science and biotechnology is framed as a given, and virtually all reports seem to 
be based on the premise that eventually XTP will become technically possible unless it is 
deliberately banned. 
However, during the period surveyed the balance in the articles gradually shifts between a 
primary focus on the potential for medical treatment to also include of focus primarily on the 
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potential problems with disease transmission. Simultaneously, the time horizon for actual 
treatments to materialise seems to get longer, rather than shorter as time passes. In the 
beginning of periods surveyed scientific experts are quoted for saying that it is a matter of a 
(relatively short) time before clinical trials will commence. Later on, experts are more hesitant 
to speculate about when this might happen. This ―delay‖ in relation to previous hope is in 
some reports made a separate object of discussion. However, at some point (largely 
coinciding with the publication of the ―Genetechnology Commission‘s‖ report, see below) 
XTP practically disappears from the media agenda. While there are continued reports of the 
difficulties encountered in controlling the risks from retro-viruses, there are no explicit 
indications that the technology has been abandoned. Rather than being reported as a failed 
technology, XTP just disappears from the repertoire of expected future treatments, to pop up 
only on a few occasions after 2002. When XTP is in fact mentioned after 2002, it is mostly 
framed as a technology, which may still have potential to alleviate organ shortages, but has 
experienced unexpected difficulties in being matured. 
3.2 Technical challenges and physical risks 
The overriding frame in the reporting and discussions about XTP concerns the technical 
challenges associated with carrying out XTP as well as the health risks associated with the 
technology. Neither the word ―xenotransplantation‖ itself nor the process it describes has 
ever become part of the common stock of knowledge the average reader is expected to be 
familiar with, as for instance genetic modification or stem cell research, which are often 
reported about without any technical jargon or explanation. Therefore, most news reports as 
well as commentaries and letters to the editor make some effort to explain what XTP is and 
the problems associated with it. Two types of challenges dominate the reports and 
discussions. Many reports describe in more or less details the rejection mechanisms at work 
in transplantation and the challenges they raise for XTP. They often explain why the addition 
of human genes to the donor pigs may be a solution. However, in terms of difficulties most 
reports focus on the risk that the organs may carry viruses, which might produce zoonotic 
diseases. During the period surveyed, the problem regarding retro-viruses in the donor 
animals‘ genes is mentioned still more frequently as the major obstacle for the technology to 
actually be used in clinical practice. The potential that viruses may travel not only to the 
patient receiving an organ, but might potentially cause epidemics in the general population is 
repeatedly quoted as the primary concern among scientific experts and regulators. This risk 
is often likened to the ―Spanish flu‖ pandemic of 1918, but the dangers from zoonotic 
infections are also repeatedly illustrated with reference to HIV/AIDS. Yet, although the 
reporting focuses on the potential dangers, these are mostly framed as challenges to be 
solved by scientific research before the technology will proceed to clinical application, not as 
a present or imminent threat to the general public. There are very few really alarmist reports 
or opinions regarding XTP. 
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3.3 The Ethics of XTP 
While most of the media reports are concerned with the technical aspects of XTP, 
addressing the questions of whether it is possible and dangerous, some articles also 
address in various ways what they describe as ―ethical‖ aspects. This framing of topics as 
―ethical‖ in facts covers a lot of different issues. 
Most of the contributions claiming to deal with ethics address the question of whether it is 
morally permissible to undertake XTP. The question is mostly related to the potential 
disturbances it may produce for the recipient patient as well as the wider collective‘s 
understanding of what it means to be a human being. This concern can be exemplified by 
letters to the editor, where the question is posed if ―one can fall in love with a pig‘s heart‖? In 
this framing, ―ethics‖ thus have to do with defining in what respect biotechnology encroach 
on our definitions of what it means to be ‖genuinely human‖ – a state of affairs which is 
considered in need of protection. According to several articles, the question of what is 
permissible when the ―genuinely human‖ characteristics are violated requires ethical 
clarification by society at large, it is not a question that can be legitimately left to the 
individual patients and their doctors. 
Yet, despite raising the question of the ethical and/or emotional reaction to the xeno-aspect 
of transplantation, by far the most contributions introduce the ‖ethical question‖ only to 
present authoritative voices (medical doctors, ethicists, theologicians) who claim that 
physical organs are immaterial to human identity or that the question is insignificant 
compared to the human lives that can potentially be prolonged or saved. 
By far the majority of contributions present the technology as relatively unproblematic or 
benign from an ethical perspective, and variations of the argument that having a pig‘s heart 
implanted is not worse than eating pork are much more frequent than concerned voices. 
Likewise, animal welfare is introduced as an ethical issue, but mostly dismissed as a 
problem by arguing that we already have an instrumental/exploitative relationship with pigs. 
For instance, the chair of the Council for Animal Ethics states that: 
―Therefore saving human lives cannot possible be more ethically 
objectionable than the already widely accepted breeding of pigs just for 
consumption – that is a normalisation by comparison to other, well known 
practices where animal welfare issues are settled. Secondly, it is argued that 
transgenic pigs bred for transplantation purposes are likely to be treated far 
better than pigs in industrial production." ―The pigs that will be bred in the 
project will be treated better and have a better life than ordinary production 
pigs. Furthermore, I believe this will contribute to raise the general level in 
pig production. And if people know that pig organs are used to save human 
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lives, it might contribute to raise people‘s respect of the pig as an animal‖ 
(quoted in Politiken, January 29
th
, 1999). 
Two additional issues, which can be labelled ―ethical‖ and are discussed thoroughly in some 
of the TA activities reported below, only find their way into just a few media reports. One is 
the question of how to weight the (potentially huge) benefits for the individual patient, whose 
life may be prolonged with a pig‘s organ, against the (unknown) risks of transmitting 
diseases to the population at large. Nor is the expected need for continued monitoring of 
patients that has received animal organs to contain the risk of contamination really touched 
upon as an ethical question. In media reports, the question of contamination is dealt with 
almost exclusively as a question of adequate controls of risks, which is framed as an issue 
that requires more knowledge and better regulation, not as a question of weighing different 
values against each other. One explanation for this could be that it is taken for granted that 
no treatment should be allowed if it exposes anybody else to a risk. Many articles mention 
there is a risk of transmission of diseases, but the problem is consistently framed as a need 
for more knowledge, adequate risk assessment and a precautionary regulatory approach. 
Only very few articles presents this as an ethical issue, as a value based trade-off between 
different goods. 
The second question regards the costs of XTP, should it become a more common 
procedure, and its effects on public health care spending. This issue was raised in the public 
debate as early as 1991 in a book by a science journalist, Gitte Meyer, debating different 
challenges arising from novel biotechnologies (Meyer 1991). However, according to Meyer, 
this – potentially extremely important – question never found any resonance with the medical 
science establishment (Interview Science journalist). In any case, the question of the 
potential costs of XTP is virtually absent from media reports – possibly because the 
technology was never close enough to clinical application to actually generate any public 
interest in the potential costs. 
3.4 Economic interests in XTP 
While the potential cost of XTP and the burdens it might place on the public health care 
system is absent in the media reports, another economic issue is repeatedly brought up, 
namely the question of the economic incentives driving modern medicine and biotechnology. 
While most reports dealing specifically with XTP make reference to the organ shortage 
problem, but rarely touch on the financial burdens this may place on the public health care 
system, XTP is often mentioned in passing in relation to other biotechnologies such as 
cloning and stem cell research, which have raised much more public concern and 
controversy. In these contexts addressing biotechnology more broadly, a more critical stance 
can be observed in many reports focussing on the profit motives driving the technological 
development. In this manner, some media reports associate XTP to technologies that are 
attracting more adverse publicity. However, in these cases XTP is mostly mentioned in 
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passing, not given any individual treatment. It is not reported anywhere that much of the 
work on XTP was carried out by pharmaceutical companies looking to sell organs along with 
immunosuppressive medicine. Therefore, no linkage appears to exist between the public 
imagery of XTP and the profit-motives driving biomedical research, as for instance in the 
debate on GMOs. That industry interests may be a driving force in the development of XTP 
was not really treated in the public sphere. 
3.5 The status of regulation and the need for public debate 
While XTP in most media reports is framed as a technology that is likely to be introduced in a 
few years – though the time perspective tend to get longer rather than shorter during the 
period surveyed, only for the topic to practically disappear from media reports – some 
contributions raise the issue that the regulatory framework is not up to date and risk being 
taken by surprise by rapid technological developments. Concerned politicians and scientific 
experts are quoted for claiming that the area is wholly unregulated in Denmark. Especially 
the risk of transmitting diseases across species barriers is described as a problem that 
requires novel regulation. Therefore, several calls are made from medical doctors as well as 
politicians that it is important that Denmark has a public debate about the risks involved and 
how they can be properly regulated in a precautionary manner. Eventually, this perception 
that regulation was insufficient led to the political initiatives recounted in the following – 
though likely more a result of concerns articulated in expert circles and reported in the media 
than the outcome of any genuine public concern manifested in the public sphere. 
This summary interpretation of the framing of XTP in the Danish print media obviously does 
not give a precise picture of what the population in Denmark thought of XTP. However, it 
gives a picture of the kind of framings available to participants in the public debate at the 
time when technology assessment and policy making activities were taking place. This said, 
it should be noted that XTP as such has not received much media attention at any point in 
time and has largely remained an elite concern. 
3.6 Existing data on public perceptions 
In the 2002 EuroBarometer survey more than 80% of the Danish population report that they 
have heard about the concept of XTP (the word itself is not used in the survey, which speak 
of ―introduction of human genes into animals (eg pigs) to produce organs (eg hearts) for 
human transplants). At this point in time public opinion was divided between approximately 
25% of what the EuroBarometer analysts call ―supporters‖, approximately 50% ―risk tolerant 
supporters‖ and approximately 25% ―opponents‖. This was a significant growth in public 
support compared to a similar measurement done 6 years earlier in 1996, where especially 
the moral reservations to XTP appears to have to have subdued – possibly in the light of 
other, even more transgressing novel technologies appearing in the public sphere in the 
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meantime, such as cloning and embryonic stem cell research (all numbers drawn from 
Allansdottir 2010). 
In complement to the EuroBarometer surveys qualitative studies on public perceptions of 
biotechnology were carried out in a number of European countries including Denmark 
(reported in Wagner et al 2001). In the fall of 1999 and the spring of 2000 a series of six 
focus groups interviews were conducted, which investigated the nature of public perceptions 
of biotechnology (reported in Wagner et al 2001). The transcripts of those focus groups have 
briefly been re-examined for the present report.
2
 
The focus group interviews focus on a broad range of issues in relation to biotechnology, 
such as the acceptability and desirability of different applications of modern biotechnology in 
both agriculture and medicine, whether such applications ought to be assessed according to 
criteria of risk or ethics, perceptions of the role and responsibility of different social actors 
such as scientists, regulators, politicians and NGOs etc. 
When re-analysing the transcripts with a particular focus on xenotransplantation, two issues 
emerges as particularly noteworthy. First, XTP is not a very pertinent issue in the discussion 
compared to other technologies, which strengthens the conclusion above that XTP was 
largely an elite concern. Second, there is a significant ambivalence in the assessment of 
XTP.  
Although XTP was one of the (potential) technologies mentioned on cue-cards handed out 
by the interviewers, it did not attract much attention among the participants compared to 
other topics, which clearly triggered more responses. This pertains in particular to cloning of 
animals and the prospect that this technology might be used on human beings, and 
genetically modified food. Both of these topics had been intensely covered by the media 
following the announcement of Dolly and the Europe-wide contestation of GMO products. As 
a consequence, these applications triggered most recognition among the focus group 
participants. There was some confusion among the participants as to whether XTP had 
actually been carried out between animals and human beings, as some participants had 
heard ―rumours‖ that this had indeed happened, either from pigs or primates. 
As reported in the general conclusions from the project (Wagner et al 2001) there was 
significant ambivalence regarding many applications of modern biotechnology. This 
pertained in particular to XTP, which generated a number of comments on the 
―unnaturalness‖ of crossing species barriers, which were intuitively rejected as an 
undesirable development. Comments were also made regarding the heart as the seat of 
                                                     
2
 The interviews were conducted by as part of the EU project ‗Life Sciences in the European Public‘. The Danish 
team consisted of Professor Arne Thing Mortensen (Roskilde University), Assistant professor Erling Jelsøe 
(Rosklide University), Mercy Wambui Kamara and Assistant professor Jesper Lassen (The Royal Veterinary and 
Agricultural University, Denmark). I am grateful to the authors for kindly putting their data at my disposal.  
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emotions, and consequently as something one should be careful tinkering with. One group 
touched upon the question of whether one could continue to consume pork form pigs with 
human genes added, though without the term cannibalism being used. The overall picture 
emerging from the focus groups is one of significant moral reservations against XTP. 
On the other hand, many interviewees also expressed a more utilitarian stance that if XTP 
offered the possibility to save the life of people, possible themselves or someone next of kin, 
it would be cruel and impermissible to reject the technology out of hand. 
Most comments were critical of XTP on ethical grounds or as ―gut reactions‖ against 
something considered unnatural. None of the participants seemed aware of the discussions 
regarding the risk of transmission of zoonotic diseases, and the question regarding to 
potential costs of XTP were touch upon only very superficially. 
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4 XTP in the Danish TA Field 
The concerns about different potential consequences of XTP, which were articulated in the 
scientific community and also to some degree found their way into the public sphere, led to 
some specific policy initiatives in Denmark. However, to understand these specific initiatives 
it may be helpful to first say something about the context in which they took place. In 
particular it is pertinent to try to explicate some characteristics of the interplay between the 
public sphere, the political level and selected ―debate-institutions‖, which are central players 
in the governance of modern biotechnology in Denmark. 
In the international literature on public engagement with science and technology, Denmark is 
often pointed out as a front runner and role model, which might be a source of inspiration or 
even imitation (e.g. Joss and Durant 1995). This is so for several reasons. Some of the back 
ground conditions have to do with the country‘s relatively high degree of cultural 
homogeneity, an egalitarian political culture and a tradition for public and popular education 
(Folkeoplysning, people‘s enlightenment) dating back more than a hundred years (Cronberg 
1995). However, there is also a particular institutional locus for public engagement with 
science and technology, the Danish Board of Technology (DBT), which has emphasised 
participatory modes of technology assessment in a particular manner since its founding in 
1985. The Board was an attempt from (parts of) the parliamentary system to give an 
institutional locus and channel to the grass root activities that had emerged in relation to 
(nuclear) energy policy and biotechnology in the preceding 15-20 years and bridge a 
perceived gap between experts, politicians and the public. The DBT has attracted significant 
international attention for its particular approach to public involvement with technology 
assessment (Klüver 1995). The Board has arguably been an important vehicle for the 
understanding and acceptance among elite decision makers that ordinary citizens can be 
both sufficiently competent and interested in novel technologies to have a say in their 
governance. 
However, when it comes to the regulation of biomedical technologies, there is another 
institution, which is equally important in regard to addressing public concerns over new 
technologies, the Council of Ethics (CoE). The Council was established by Parliament in 
1987 to provide advice to the legislature on ethically sensitive issues in the life sciences and 
to stimulate public debate on such issues. It is not obligatory for legislators to hear or heed 
the advice on the Council, but the parliament nonetheless frequently solicits advice and often 
follows the recommendations. The Council is also free to take up issues on its own initiative 
and thus serves an early warning function. The CoE does not apply participatory methods 
when producing policy advice, but it has played a significant role in Danish governance of 
biomedicine as a moderating force in the face of the rapid technological innovations. 
Although the CoE is compiled of biomedical experts, ethicists, theologians and a few ―lay 
people‖ (usually individuals originating from the cultural sphere such as writers, journalists 
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etc.), the Council understands itself as a guardian of the public interest, which is often 
equated with being a modifying force in the face of rapid biomedical developments. One 
interviewee, for instance, described the role of the Council as exercising the privilege to 
expend the time necessary for reflection, which is rarely available to political decision 
makers. 
In Denmark public concerns over and debates about new biotechnology proliferated during 
the 1990s, in particular in relation to two technological trajectories: the introduction of GMOs 
in the agro-food sector and new reproduction technologies. Biotechnology became 
particularly politicised through the combined effects of the introduction of GMO, which 
coincided closely with the revelation of a link between BSE and nvCJD (i.e. admitting that 
―mad cow disease‖ could spread to human beings), followed quickly by the arrival on the 
world scene of Dolly the cloned sheep. These events in combination raised public concerns 
about the safety of new products and the ability of scientific experts to control the risks 
affiliated with them. It also placed ―ethical‖ questions concerning the motives behind and 
moral acceptability of these new technologies on the public agenda. This resulted both in a 
surge in NGO mobilisation and activity, increased media coverage and public debate as well 
as a number of policy initiatives aimed at addressing some of these concerns in various 
ways (Jelsøe et al 2001). 
In the autumn of 1997 the ministry of trade and industry, on request of trade organisations in 
the food sector – which demanded some clearer political signals regarding the use of 
biotechnology – compiled a commission to unravel the reasons behind the continued public 
concerns regarding in particular GMOs and provide the basis for more inclusive public 
debate on how to apply the novel genetic technologies. This committee, called BioTIK (a 
verbal contraction of ―biotechnology‖ and ―ethics‖ in Danish) presented a report in the 
summer of 1999, which formulated a set of ethical guidelines to direct the governance of 
biotechnology across all domains of application (Hansen 2010). It also produced a number of 
recommendations on how to ensure a continued public debate on these issues and make 
sure the ethical principles would be taken into consideration in the drafting of relevant novel 
legislation. One of these recommendations was that a better coordination should be ensured 
between the different advisory bodies that deal with biotechnology. 
However, at the time of publication of the BioTIK report collaboration had already been 
initiated between various public bodies working on issues related to the assessment and 
governance of biotechnology. This was instigated following a parliamentary debate on 
cloning in the wake of the announcement of Dolly. An umbrella organisation consisting of the 
Danish Board of Technology, the Council of Ethics, the Council on Animal Ethics, the Danish 
National Committee on Biomedical Research Ethics and the Inspectorate on Animal 
Experiments was launched in 1998 under the name BIOSAM. According to some 
interviewees there was really no strong desire for this umbrella among the involved 
organisations. It happened on the request of the government, which wanted a stronger and 
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more unanimous base of advice on how to govern the novel biotechnologies through 
synergies in the advisory system. In the view of some of my interviewees the desire for this 
collaboration originated in a political compromise to accommodate two smaller centrist party 
(Centrumdemokraterne and Kristeligt Folkepart), which took a particular interest in 
biotechnology. As a result, funds were made available for collaboration, and the involved 
organisations started to look for topics, on which it would be relevant to collaborate. At this 
time XTP was rising on the horizon internationally. Interviews with people centrally placed 
within the BIOSAM collaboration has not been able to establish more specifically exactly why 
XTP was selected for attention (Interviews Bioethics professor, Former Chair of CoE, 
Member of CoE Staff). However, the topic was well suited to the institutional purpose of 
BIOSAM. It bundled together issues regarding physical risks from an emerging technology, 
ethical issues pertaining to both the human and the animal domain as well as questions 
concerning priorities in health care expenditure. 
In retrospect, some interviewees indicated that the selection of XTP was as much a matter of 
finding a suitable topic for the BIOSAM collaboration, which was relevant for all the involved 
organisations, as it was an expression of a pressing need for either ethical or regulatory 
clarification. However, other interviewees did not quite agree with this cynical reading of the 
process. While not denying the topic was well-suited to facilitate collaboration in the 
organisational constellation of BIOSAM, they insist that XTP raised some genuine concerns 
at the time, and it is only in retrospect that concerns over XTP can be deemed premature 
and perhaps even unfounded. The selection of XTP for closer examination followed relatively 
closely upon the much more controversial discussions regarding GMOs and animal cloning. 
Some members of the organisations in BIOSAM foresaw that XTP might generate similar 
public concerns in the future and suggested that BIOSAM should try to deal with this 
prospectively and proactively. As such, XTP indeed fitted the BIOSAM collaboration well, as 
it pertained to all the involved organisations different mandates. Therefore, most of the policy 
activities regarding XTP in the following years were initiated by or at least affiliated with 
BIOSAM. 
The Council of Ethics was a central organisation in BIOSAM. However, former members of 
the Council differ in their assessment of how important XTP was considered to be at the 
time. One interviewee recalls that XTP never generated much interest in the council 
(Interview Former Chair of CoE). In the assessment of the Council, XTP does not involve 
―identity carrying organs‖, which makes it less challenging and controversial from the kind of 
ethical perspectives occupying the CoE. By ―identity carrying organs‖ the CoE understand 
primarily the brain as the seat of consciousness, visible features of the physical appearance 
and the genetic code amendable to intergenerational transmission. Consequently the 
primary concerns are about the control of physical risks, which the Council considers a more 
technical aspect and hence at the fringes of its remit (Interview Member of CoE Staff). 
However, another former member of the Council recalls that the ‖yak-factor‖ – the immediate 
repulsion by the transgression of species barriers and the idea of having an animal organ in 
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your body – was discussed by the Council, but was ―overruled‖ by more ―rational‖ 
arguments, suggesting that fatality is worse and that most people have no reservations 
against eating pork (Interview Former Member of CoE). 
Although several of the organisations involved in the BIOSAM collaboration have as a 
central task to address the concerns of the public in relation to (bio)technology and convey 
this to policy makers, the activities related to XTP were not participatory in nature. The 
guiding idea was, it the words of one interviewee, to ―generate a broader discussion than 
had been common practice until this point in time‖ (Interview Bioethics professor). In 
comparison to the public debates on other technologies (e.g. GMO, cloning and stem cell 
research) several interviewees involved with the XTP activities in BIOSAM recall that the 
topic was remarkably uncontroversial. Some of them suggest that there was a strong desire 
among policy makers and scientists to avoid a repetition of the controversies regarding 
GMOs and cloning. In regard to GMOs several of the interviewees articulate a shared 
assumption that the general public was somehow unprepared for the novel GM technology, 
and that a more thorough public debate about the purposes and regulation of the technology 
at an earlier stage could have eased its introduction into society and onto the markets. 
As a consequence of this diagnosis, which appears to have been shared among the 
organisations involved in BIOSAM, it was seen as desirable to have a broad debate and 
initiate regulation of XTP before scientific developments progressed anywhere near clinical 
applications. However, several interviewees suggested in retrospect that the desire to initiate 
debate may in fact have been premature in two respects; 1) XTP never (at least not so far) 
reached a stage of clinical maturity that made it necessary to legitimate its application 
beyond the confines of basic research laboratories. 2) XTP did not seem to generate any 
particular potential for controversy. Following the announcement of Dolly the cloned sheep, 
the Danish Parliament passed a resolution that the cloning of animals should be prohibited in 
Denmark until further notice. This type of resolution is an instruction from Parliament to the 
Government to prepare legislation, which Parliament can then subsequently pass. However, 
the resolution was never turned into proper legislation and consequently lost legal force 
when Parliament was dissolved for a general election. The subsequent Parliament never 
actually passed any legislation. Therefore, researchers kept pressing the minister of science 
for legal clarification by repeatedly producing cloned bovine embryos and bringing them still 
closer to delivery. This was disputed in the Danish media at the time and animal cloning was 
strongly criticised by animal welfare groups. However, nothing similar in terms of public 
attention was ever seen in relation to XTP. In fact, one interviewee working in the 
biosciences suggested that XTP was always seen as ―the benign biotechnology‖, one where 
the benefits were so obvious and the ethical problems insignificant, that he and his 
colleagues tended to use XTP as a ―lubricant‖ to make other biotechnologies more palatable 
in the wider public (Interview Professor of Veterinarian Embryology). XTP was used to 
symbolise (potential) applications of genetic engineering, which were unequivocally 
beneficial. 
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A similar comparison can be made with the debates on GMOs. Where GMOs generated a lot 
of concern and hostility among especially environmental NGOs, there was never any similar 
adverse attention to medical research on XTP from animal protection organisations. As one 
interviewee expressed it, animal protection organisations do not wish or need to engage with 
complex problems pertaining to the welfare of human beings, there are plenty of other, more 
pressing animal welfare issues, were there are no immediate counterweighing interests 
(Interview Bioethics professor). Hence, compared to agricultural biotechnology no 
mobilisation potential has been generated by XTP in Denmark. There may have been a 
certain ―yak-factor‖ – the crossing of species boundaries were seen by some people as 
repugnant – but given that it is framed as something that might save lives and nobody ever 
would be treated against their will, the prospect of the procedure itself never generated any 
noteworthy public resistance. Likewise it seems that the prospect of a transfer of viruses 
between animals and human beings remained too distant to generate any genuine public 
concern, most likely very few members of the public were aware of this risk. 
However, even if it seems in retrospect that XTP did not generate the kind of concerns or 
controversies in public, which is often motivating more elaborate, perhaps participatory, 
technology assessments, it did generate some TA activity, as will be described in the 
following. 
In March 1999 BIOSAM (with the DBT as the executing organisation) together with the 
University of Copenhagen organised an expert hearing with four researchers from Denmark, 
Sweden, the US and the UK. These were all biomedical experts, who were invited to talk 
about prospects and challenges affiliated with the potential use of XTP. The minutes from 
the meeting reveal a high degree of optimism among the experts regarding the technical 
prospects for XTP aided by genetic modification of the donor animals, but a more hesitant 
and divided attitude towards the possibilities of managing the accompanying risks of 
infections through retro-viruses. The meeting did not produce a shared conclusion or 
recommendation, but it transpires from the minutes that the experts agreed that a cautious 
step-by-step approach, where gradually more and more steps towards clinical applications is 
accompanied by a close monitoring of risk, would be the best way to proceed. The 
participants stated that it is important that developments in XTP are not forced by renegade 
scientists or commercial pressures. If progress is forced prematurely, problems that are 
unavoidable in developing a technology such as XTP might create backlashes for this 
otherwise promising technology. At this point the experts summoned by the TA system thus 
still consider XTP as a promising technology, although concerns about unwanted side-
effects are beginning to overshadow the positive expectations. Yet, the issues are being 
discussed in rather linear terms, as a given trajectory, which can be followed ―step-by-step‖, 
whereby only the pace of progress may need to be moderated. The chair concluded that 
there had been less disagreement among the experts than he had expected, but that 
BIOSAM now had a good case to present to the public. 
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A summary of the conference with the politically most pertinent issues was then presented to 
the public in the form of two newsletters from BIOSAM (BIOSAM 2000, 2004). As part of its 
introduction, the first newsletter stated that: ―In Denmark, there is currently no particular 
legislation regulating xenotransplantation. There is thus a need for a debate and political 
clarification about whether we wish xenotransplantation to be introduced in Denmark, and, if 
so, a debate about what demands should be made to experiments with and use of 
xenotransplantation.‖ (BIOSAM informerer 1999, 2000). It was, however, also lamented that 
―Denmark is practically void of research in this field and the government does not possess 
the competences to follow the international development‖ (BIOSAM 2000). 
Following upon this, in February 2000, the DBT and the Council of Ethics organised a one 
day hearing on XTP at the request of the standing committees on health and research in the 
Danish Parliament. At this meeting the scope of the agenda is somewhat broader, going 
beyond the strictly scientific issues. This is reflected in the composition of the panel of invited 
experts, which includes natural scientists, ethicists, a lawyer and an economist specialised in 
health care economics. The themes elaborated in the hearing were compiled under the 
following headings: ―Organ transplantation‖, ―Xenotransplantation‖, ―Risks of transfer of 
virus‖, ―Health economic considerations‖, ―Regulatory considerations‖, ―Ethical implications in 
relation to humans‖, ―Ethical implications in relation to animals‖ and ―International 
experiences in regulation‖. As can be seen a broad range of themes were elaborated 
through expert presentations and Questions & Answers sessions between experts and 
parliamentarians (Danish Board of Technology 2000). 
One theme, which proved to be significant for the subsequent political treatment, was the 
fact that XTP was practically unregulated by law in Denmark. It was made clear that 
experiments with XTP would have to be approved by research ethics committees at a 
regional level, as is standard practice that medical research is approved by regional research 
ethics committee. However, these committees serve to protect the patients participating in 
medical experiments from unethical treatment and nothing in Danish legislation would 
prevent a doctor from treating a patient with an animal organ as a last resort and outside 
formalised experiments. In this case, the doctor would only be obliged to think of the welfare 
of the patient, not about the risks of transmission of viruses or other diseases. In this case 
the patient would have to give his or her informed consent, but this could not obligate the 
patient to take part in any subsequent monitoring schemes. This state of affairs raised some 
concerns regarding whether existing legislation was suitable and sufficient to handle XTP in 
a responsible fashion. 
This lack of regulation was to some extent rectified in January 2001. The Council of Ethics 
and the Danish National Committee on Biomedical Research Ethics issued a joint statement 
to the regional scientific ethics committees. This stated that all clinical trials with XTP raise 
fundamental question of a broader character regarding their acceptability in the light of 
uncertainties and possible risks. Therefore, all such experiments must be deferred to the 
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National Committee on Research Ethics. As far as the present research has been able to 
establish, the initiative for the moratorium came from lawyers in the Committee on Research 
Ethics, who were concerned with the fact that the risks of zoonotic diseases was a genuine 
threat to public health, but in fact the Committee had not statutory basis to prevent such 
experiments, as their jurisdiction pertained only to the welfare of the patients that might 
participate in experiments. Therefore, they suggested a moratorium until the issue could be 
legally regulated. They did so in collaboration with the Council of Ethics (with which close 
ties existed due to the movement of central staff between the two organisations) in order to 
underline the ethical importance of this precautionary approach. The moratorium did not 
completely do away with the possibility that individual doctors in principle could carry out 
xenotransplantation outside of controlled experiments. In practice, however, it meant that no 
experiments would take place without centralised approval. Yet, this did not quite entirely 
satisfy the more concerned politicians, who felt that formalised legislation was required in 
this domain. At this point in time, the governance of XTP therefore briefly becomes the object 
of direct political attention and intervention. 
However, before describing this process in more details, one further finding of the Danish TA 
system‘s dealings with XTP must be mentioned. When regulating such areas in Denmark, 
there is a long tradition of hearing actors with a stake in the development in various ways. In 
a case like xenotransplantation this would include for instance patient organisations. This did 
not happen in any of the activities recounted above. In Denmark there is an organisation for 
patients with kidney diseases (Nyreforeningen), which organises and represents patients in 
dialysis treatment and kidney transplanted. When interviewed about their views on XTP, the 
(recently appointed) director explained that the organisations had no interest whatsoever in 
supporting or furthering the technology. The organisation does not see XTP as a feasible, 
potential source of treatment. In their view, the lack of organ donors is an organisational 
issue, which should be solved through a better system to motivate and organise potential 
human donors. Furthermore, the organisation feels that the ability to maintain and raise the 
level of organ donation will not benefit in any way by the organisation participating in public 
debates on the prospects of xenotransplantation. In short, they did not wish to engage with 
the issue at all (Interview Patient organisation). 
Although patient organisations – especially for more rare diseases – can be idiosyncratic and 
shaped by a very few, vocal activists, it does seem remarkable that in this case a significant 
sum of money have been spent in the hope to develop a medical technology for which the 
potential beneficiaries show no interest whatsoever, rather to the contrary. Furthermore, 
patient organisations have not participated in any of the technology assessment exercises 
recounted above. It seems that all initiatives have been generated by professional scientists, 
either concerned with the public legitimacy of their work or the kind of risks entailed in it. 
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5 XTP in the field of policy making 
A few days later after the de facto moratorium on XTP was announced by the CoE and the 
Committee on Research Ethics in January 2001, a debate was held in the Danish 
Parliament, initiated by the Christian Democratic Party. There was no immediate link 
between the issuing of the moratorium and the debate in Parliament, as the debate was 
scheduled much earlier as a follow up to the hearing held the year before. Rather, both the 
moratorium and the parliamentary debate can be said to be occasioned by the previous 
hearings and the kind of concerns that were raised. The Christian Democratic Party, which 
initiated the debate, was a small a centrist party with only four MPs, which often sought to 
profile itself on ―ethical issues‖, such as a restrictive attitude to abortion, animal welfare and 
a cautious attitude towards novel biotechnologies such as cloning, stem cell research etc. 
According to their spokesperson, concerns about XTP were a ―natural‖ subject for them to 
address, as ―everyone expected for us to take up things like this. If we had not taken up the 
issue, probably nobody would, back then. Today, luckily, this has changed‖ (Interview 
Parliamentarian). The Christian Democrats were mostly concerned about the unchecked 
risks that might be affiliated with XTP, but also felt that the ethical aspects deserved to be 
explored thoroughly by political decision-makers, like ―… how many animal organs can you 
put in a human being and still call it a human being?‖ (Interview Parliamentarian). The party 
therefore raised an inquiry (‖forespørgselsdebat‖) in the Parliament. This is format of debate 
where the minister(s) responsible for a given area has to give an account of the status of the 
legislation, policies and potential problems to the Parliament, which can then decide to 
request ministers to do something, for instance prepare a particular piece of legislation.
3
 
The Christian Democrats posed the following question to the ministers of research, health 
and justice: ―How will the government ensure that research into and experiments with 
xenotransplantation only takes place with due consideration for the necessary safety, that 
possible trials only happen in controlled and contained circumstances, and that the welfare 
of the donor and experimental animals are carefully considered?‖ 
The responsible ministers informed the Parliament that 1) with the recent announcements 
from the Central Committee on Research Ethics and the Council of Ethics, all research 
should be approved by the Central Committee on Research Ethics, 2) that public hospitals 
and universities will be instructed not to carry out any experiments until the risks and 
regulation is further clarified
4
 and that 3) research on xenotransplantation was unlikely to 
                                                     
3
 This was the format of debate in which a previous Parliament request the Government to ban cloning, which, 
however, never actually made it to a bill – see above. 
4
 In principle, the government cannot instruct universities in Denmark about what they can and cannot do 
experiments on (outside proper legislation) as there is freedom for research. However, the medical faculties of the 
universities are so closely integrated with the public hospitals in regard to clinical research that in practice such 
political instructions will be heeded.  
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induce any particular animal welfare problems, which were not covered by the existing 
legislation and monitoring. 
In the issuing debate the Christian Democrats proposed that Parliament should decide to 
ban xenotransplantation in Denmark until further notice, such that the decision to resume 
such research would demand by a renewed parliamentary decision. However, practically all 
other parties in the parliament considered this as excessive, and proposed an alternative 
that foresaw a de facto moratorium but no legislation. They suggested that 1) experiments 
with XTP should be approved by the scientific research ethics committee system (and not by 
Parliament), but 2) the minister of research should form a committee to undertake a review 
of the prospects and risks presented by a number of new biotechnologies, not just XTP, in 
order to clarify the need for new legal and/or regulatory measures. 
This motion was carried by the Parliament, and this was the occasion for the formation of the 
―Genetechnology Commission‖. This Commission was subsequently compiled with a number 
of scientific experts, ethicists and ministerial representatives. Their mandate was to elucidate 
the possibilities and challenges affiliated with four emerging technologies (XTP, gene-
therapy, stem cell research and genetic diagnosis) in order to stimulate public and political 
debate on an informed basis and make suggestions for necessary legislative initiatives. The 
commission was compiled by the Ministries of Research and Health and included active 
scientists from the respective fields, representatives from the ministries and from the Council 
of Ethics, the Council of Animal Ethics and the Danish Board of Technology. This kind of 
committee is standard practice in policy formation in the Danish political system. 
About the time this commission initiated its work, in May 2001, the National Board of Health 
(highest medical authority in Denmark) issued an instruction to all Danish hospitals that no 
XTPs should be carried out in Danish hospitals outside controlled experiments approved by 
the Danish National Committee on Biomedical Research Ethics until the question of risks 
involved in such research had be further clarified and further regulation was put in place. 
This turned the principled decision in Parliament regarding a moratorium into actual policy. 
Although no legislation was issued, in practice such an instruction from the National Board of 
Health meant that a moratorium was de facto in force. 
Several members of the Committee have been interviewed for the present inquiry. None of 
them were able to recount why precisely those four technologies were included for 
examination. The Christian Democratic parliamentarian, who raised the debate initially, 
suggested that there was an ―economy of scale‖ involved; if the government had to compile 
a commission, they might as well add more topics, on which it thought legislation might be 
necessary in the future. The chair of the committee, a professor of clinical biochemistry, 
suggested that substantively it made sense to elucidate challenges affiliated with several 
technologies, which might potentially serve equivalent purposes in medical treatment. In 
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particular XTP and stem cell research were seen as different approaches, which might 
potentially deliver treatments for the same diseases through different means. 
In the report from the Committee, which was published in the fall of 2002, the development 
of XTP is motivated in the large gap between supply and demand of organs for 
transplantation. However, it also notes that ―The overall hope is that xenotransplantation in 
time may become a routine treatment. There are, however, a number of both technical, 
biological and ethical problems concerning xenotransplantation, which makes it difficult to 
decide whether the technology will be feasible as a form of treatment within a foreseeable 
future‖ (Genteknologiudvalget 2002: 67). The report goes on to elaborate these problems. 
Especially the problems related to the transmission of viruses from donor animals to human 
being are quoted as a reason why XTP is not expected to become a clinical reality for a 
foreseeable future. 
All the members of the committee interviewed for this inquiry recollect that XTP was not a 
very big or controversial part of the work of the committee, and was largely overshadowed by 
the other topics. One member suggested that the assessment at the time was that XTP was 
rather unlikely to actually happen in a foreseeable future. According to the interviewed 
members and the Commission‘s secretary there were significant debates in the commission 
about stem cell research, where in particular members from the research community and the 
representative from the Council of Ethics engaged in elaborate debates about how to 
regulate the use of human embryos. Nothing similar took place in relation to XTP on which 
all members concurred that the crucial issue (apart from the technical issue regarding 
rejection of the organs) was whether the risks of contamination could be dealt with in a 
satisfactory manner. 
In October 2002 the commission delivered its report, which concluded that no further 
legislation or regulation was required for XTP for the time being. It was assessed that clinical 
applications of XTP has been pushed off into the future on account of the risk of 
transmission of viruses. Consequently, the existing de facto moratorium was a sensible and 
sufficient regulatory tool, which only would require review in the case of significant 
international breakthroughs in XTP research. The commission makes a number of 
recommendations regarding the other technologies involved in its mandate, and it was the 
immediate occasion for a change of the law on assisted reproduction (pertaining to the use 
of ―surplus‖ embryos for stem cell research, see e.g. Horst 2008).   
Since then there has been no further policy activity or measures concerning XTP in 
Denmark. 
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6 XTP Timeline in Denmark 
Date Central policy events Other events and developments 
11.1991  The word ―xenotransplantation‖ 
appears for the first time in a 
Danish newspaper as well as a 
book debating novel 
biotechnologies (Meyer 1991) 
12.1995  The first letter to the editor 
containing the word 
―Xenotransplantation‖ occurs in 
a Danish newspaper 
1998 BIOSAM is formed as a collaboration between 
The Danish Board of Technology (DBT), The 
Council of Ethics (CE), The National Danish 
Committee on Biomedical Research Ethics 
(CVK), the Inspectorate for Animal Experiments 
and The Council of Animal Ethics (CAE). 
BIOSAM takes up XTP as one of its central 
areas of interest 
 
3.1999 DBT, BIOSAM and University of Copenhagen 
organize an expert hearing with 4 natural 
science experts from DK, S, USA, UK 
 
2.2000 DBT organizes a hearing for the Danish 
parliament with 8 Danish and 2 Swedish 
experts, including natural scientists, ethicists, 
one lawyer, one economist (Sweden had had a 
XTP Committee) 
 
1.2001 CE and CVK make a joint announcement to the 
regional scientific ethics committees that all 
XTP trials or preparations thereof raises 
fundamental questions and must be presented 
to the CVK 
 
1.2001 Questions/Debate in the Danish parliament, 
resulting in  
1) A de facto moratorium on XTP 
2) The formation of a ―Genetechnology 
Commission‖, examining four different 
new medical technologies (XTP, gene 
therapy, stem cell research, genetic 
diagnosis) in order to support decision 
making and public debate 
 
5.2001 The National Board of Health (highest authority 
in DK) issues an instruction to the county 
authorities (in charge of hospitals) that no XPTs 
should be carried out in Danish hospitals 
outside controlled experiments approved by the 
CVK until further regulation is in place 
 
10.2002 The Genetechnology Commission delivers its 
report, concluding that at present no further 
legislation or regulation is required in the XTP 
domain 
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7 Interpreting the Danish case 
When compared to a number of other modern biotechnological applications, which were 
debated around the same time, e.g. cloning, stem cell research, GMOs, it is safe to say that 
XTP has drawn relatively little public or policy interest in Denmark. This can probably be 
ascribed to two factors in particular: 
1. There was never any really strong interest in XTP from the scientific community or 
commercial operators. Apart from a few dedicated transplantation surgeons (who 
went into retirement as the international developments really took off), nobody 
seriously promoted a move towards clinical applications. Ever since, XTP appears to 
have been a rather dormant field within the scientific community in Denmark, where 
international developments are monitored, but no researchers engage actively with 
the field 
2. Simultaneously, XTP was framed in the public as a relatively benign application of 
genetic engineering with a well-defined and uncontroversial objective. Although 
some concerns were raised regarding the ethical acceptability of the crossing of 
species-barriers, the public debate generally took a pragmatic and utilitarian view on 
XTP, based on the assumption that any transplantation would be voluntary and only 
affect the receiving patient. As a consequence, there was virtually no NGO 
mobilisation or critical interest in XTP. As explained, the most likely group of patients 
to benefit from whole organ XTP – kidney patients – expressed an outspoken 
dismay for the idea and did not engage in the debate at all.  
Yet some TA activities were initiated to clarify and debate a number of issues in relation to 
XTP. However, rather than being a response to any pressing need felt by any particular actor 
or actor coalition in the larger society, the activities seemingly arose out of the need of the 
TA systems itself. At least according to some interviewees the selection of XTP as a topic of 
debate had as much to with the need of TA organisations to find an issue on which to 
collaborate in a reasonably meaningful manner, though not all participants are willing to 
accept this cynical reading. 
This initiative followed close on the heels of other – much more prolific – controversies over 
especially GMOs and cloning techniques. XTP appeared at the time as an approaching 
technology, which shared many of the same characteristics and potential for controversy. 
This view of things embody a very linear conception of the trajectory of a technology, which 
in principles leaves only a rather passive role for TA activities – something that should 
prepare society for the oncoming technology, which will in any case arrive at some point in 
time. This linear thinking is quite common in the framing of modern biotechnology. Hence, it 
appears there was broad agreement in TA circles that it might be a good idea to raise some 
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of the potentially controversial issues in a prospective fashion. It was hoped and expected 
that experiences could be drawn from past controversies and prevent similar levels of fear 
and hostility, which some actors felt had befallen GMOs and cloning techniques. However, in 
hindsight the TA activities related to XTP are considered by several of the involved TA 
practitioners as premature (as the technology never reached clinical application) and too ―top 
down‖ as popular concerns never really manifested themselves and central potential 
stakeholders, e.g. patient organisations, did not wish to engage in the debates or were not 
invited to do so. Somehow, the patients‘ view seem to have been filtered out of the TA 
processes, possibly – as suggested by one interviewee – because the field had a ring of 
science fiction about it and nobody seriously imagined that it would progress towards clinical 
applications in a feasible future. At least, the patients‘ view of the prospect of XTP appear to 
be wholly absent from the recorded discussions among policy makers. In the end, assessing 
XTP remained an elitist undertaking restricted to some rather narrow and – to some extent – 
closely intertwined expert circles in Denmark.  
Yet, some of the same practitioners also pointed out that XTP exemplified how TA activities 
inevitably are very sensitive to the temporal developments of events. Had the technology in 
fact matured to a level of clinical applications, the appraisal might have been both pertinent 
and appropriate. If nothing else, the case demonstrated some of the difficulties involved in 
designating the appropriate and timely measures for a democratic appraisal of novel 
technologies. If instigated ―too early‖ – in phases where technological trajectories are not yet 
solidified – they may end up addressing irrelevant issues. However, if instigated ―too late‖ 
technologies – or social appraisals – may be hardened to a degree where TA processes no 
longer can make a difference. In the case of XTP the Danish TA system (which has matured 
significantly in parallel to development to the life sciences) may simultaneously have been 
both overtly sensitive to developments still only on the horizon and strangely insensitive to 
the concerns of the potential beneficiaries of the technology in question. 
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8 The Danish Political System – Background information for 
comparison 
This section contains information on the background variables required for WP 4 
8.1 General features 
8.1.1 Cabinets 
Denmark last had a single party government in 1982. Since then all cabinets have built on 
coalitions of at least two parties.  
1981-1992 lead by the Conservatives, including the Liberals and different constellations of 
other, smaller parties 
1992-2001 lead by the Social Democrats, including different constellations of smaller parties 
2001- present lead by the Liberals, including the Conservatives 
8.1.2 Legislature 
Denmark has only one chamber in parliament (Folketinget). 
The parliament has few organisational means of information provision. Parliamentarians 
from the governing parties are to some extend able to rely on the services of the central 
administration (ministries and government agencies). Parliamentarians from the opposition 
rely on information provided to the standing committees by the central administration, but 
also frequently use the possibility of asking questions of ministers, who are obliged to 
answer (truthfully) to the parliament. However, this often seems to serve a function in the 
political game rather than as a source of information provision.  
Interest organisations play a key role in providing information for parliamentarians.  
The Danish Board of Technology is a rather unique organisational invention, as it is in direct 
service to the Parliament, providing knowledge and recommendations on novel technology 
and socio-economic impacts of technological innovation. Most expert commissions etc. 
report to the Government rather than the Parliament. This information is obviously passed on 
to the parliament, but the parliament can only initiate such information provision indirectly (as 
was seen regarding the Genetechnology Commission) 
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8.1.3 Executive-legislative relationship 
Some observers talk about a long tradition of a ―cooperative democracy‖, where most wide-
ranging, important decisions are based on compromises including all the major (old) parties 
in parliament. However, since 2001, the liberal government has found its parliamentarian 
basis in the Danish Peoples Party (rightwing populist party) and has been criticised for 
pursuing a more divisive strategy on many issues. This has lead to a situation where the 
executive has a more dominant position vis-à-vis the parliament than was traditionally the 
case, as many important issues are negotiated among the government and its 
parliamentarian support party prior to negotiations in parliament. Formally it is the role of the 
parliament to legislate, in practise by far the most legislative initiatives come from the 
government, prepared by the ministries. However, the parliament can take initiatives that 
instruct the government to prepare legislation (e.g. the cloning issue in 1997, although this 
was not implemented due a general election) or to compile commissions to provide 
knowledge and recommendations (e.g. the Genetechnology Commission). 
8.1.4 Bureaucracy 
The central administration is politically neutral, only very few ―special advisors‖ to the 
ministers are replaced when government changes. Except for the central bank, most 
government agencies are under direct political control of the government, but most day-to-
day operations are left to the bureaucracy. Denmark has a very large public sector, 
accounting for more than half of the GDP. Of this, the state accounts for about one third, 
municipalities and regions for the rest. Consequently, the state bureaucracy is relatively 
large.  
8.1.5 Judicial review 
Judicial review plays only a minor role for political decision-making. Denmark neither has a 
constitutional court, nor specialised administrative courts. Labour unions and industry 
associations run their own judicial systems for arbitration and adjudication in industrial 
relations. 
8.1.6 Party system 
There are currently nine parties represented in the Danish parliament. Due to a low entry 
threshold (2%) and proportional representation, this is not unusual. The dominant parties – 
i.e. those that realistically can be expected to provide the prime minister – are the Liberal 
Party (currently in power) and the Social Democrats (in power 1992-2001 and considered 
the opposition leader).  
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8.1.7 Interest group system 
Denmark is traditionally a corporatist country, where the influence of trade unions and 
industry associations on politics has been very strong. Furthermore, the labour market is self 
governing through collective bargaining between unions and employer associations, usually 
with little political interference. This corporatism is currently under pressure from declining 
union memberships, decoupling of occupation and electoral preferences, diversification of 
political interests to incorporate non-economic issues, Europeanization of regulation, etc., 
but in certain respects the political system actually seems keen to maintain this particular 
―Danish model‖ rather than succumb to a more pluralist system. 
Political scientists thus refer to Denmark as an ―negotiated economy‖, ―… a structuring of 
society whereby an essential part of the allocation of resources is conducted through 
organized negotiations between independent decision-making centres in the public sector, 
private interest organisations, and financial institutions‖ (Pedersen 2006: 246), meaning that 
representatives of major societal interests are virtually always invited to the table, when 
important issues are being considered.  
8.1.8 Direct democracy 
Direct democratic instruments have primarily been employed on European issues, which 
have been somewhat disconnected from domestic politics, as cleavages in voter preferences 
on European issues often cut right through the constituencies of the main parties. Denmark 
has had five referendums on European issues (Accession to the EC 1973, Accession to the 
Common Market Act 1986, Ratification of the Maastricht Treaty 1992, Ratification of the 
Edinburgh Treaty 1993, Inclusion in the Eurozone 2000). 
Other than that, constitutional changes need to be accepted by a referendum. This last 
happened in 1953. There are no provisions for popular initiatives to initiate referenda.  
8.1.9 Political culture 
Denmark is considered to have a thriving political culture with comparatively high numbers of 
participation in various kinds of associations, political parties (though declining) and public 
debate. Also there is a tradition in Denmark to consider ―public debate‖ a prerequisite for 
competent and legitimate policy making. This means that prior to decision making, important 
issues are debated in the public sphere. The biotechnological domain is somewhat atypical 
in this respect, as the domain has experienced many more organised and formalised 
debates, for instance instigated by the Danish Board of Technology or the Council of Ethics. 
Furthermore, all legislation is passed through a hearing phase, where interested parties are 
notified and asked to submit comments. 
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8.1.10 Science-Society relations 
The question about science-society relations is quite difficult to answer in general, as there 
are significant differences between sectors. For instance, in infrastructural planning, expert 
advice often succumb to political expediency - when motorways are located to contend 
regional interests rather than where most needed, or expanded despite expert 
recommendations that this will only increase traffic and not solve any problems in the longer 
run. Likewise, crime prevention is an area where experts have little influence on policies. In 
other sectors, experts govern without much political intervention or public attention at all, 
such as construction safety. 
A number of domains such as environmental protection or biomedicine are intermediate in 
terms of expert influence. Expertise is obviously required and the state devotes significant 
sums of money to such areas. However, the role of scientific experts working in such fields 
are tempered by 1) an increasing dominance of economic incentives (e.g. economists 
replacing medical doctors as administrators in the health care sector) and 2) the need for 
public justification, which often mean that experts are required to participate in the public 
debate, serve on commissions with other kinds of expertise and sometimes organised 
interests or lay people. 
Comparatively, Denmark is characterised by an anti-authoritarian and egalitarian culture. 
One implication of this is that experts are required to justify their judgements (often in public). 
In the interviews conducted for this study, it transpires that scientists generally accept that 
some political restrictions and regulatory oversight is beneficial as it helps to ensure their 
social legitimacy, and they find that the political system (including its bureaucrats) are 
generally willing to find compromises that balance this need for public legitimacy with 
conditions that do not inhibit the research, they wish to conduct. 
8.1.11 Constitutional division of territorial power 
Formally, public administration is divided between three levels in Denmark, the state, the 
regions (of which there are 5 after the system being overhauled in 2007) and the 
municipalities (of which there are 98 as of 2007). The regions administer the health care 
system and practically have no other significant functions. The municipalities provide social 
service, primary school education etc. The municipalities have taxation rights, but their 
freedom to act independently is rather circumscribed in most respects. Hence, all political 
power except in local affairs is located at the state level. 
8.1.12 Electoral system 
The electoral system is proportional with a 2% entry barrier. In principle, this should give 
easy access to new parties. It is relatively easy to be admitted to run in elections. However, 
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in practice it has proven quite difficult for novel parties to consolidate themselves in the 
political landscape. There was a major reshuffling of the party landscape in the 1973 
election. Since then, there have only been minor adjustments with smaller parties entering 
for one or two election terms. This stability is partly due to the ability of existing parties to 
include novel themes. For instance, environmental problems have been admitted to the 
agenda of first the leftists parties, since then being variously adopted by other parties, thus 
not leaving space for a Green Party to gain representation. 
8.2 The field of biomedicine/innovation policy 
Relative to its size, Denmark has a strong position in biotechnology, in industry, agriculture 
and biomedicine alike. This is visible for instance in some major Danish companies like 
NovoNordisk (world leader in insulin-production), Novozymes (world leader in enzyme-
production and biofuels), Danisco (world second in enzyme production), Chr. Hansen (food 
additives), Carlsberg (beer production) etc, most of which have a long history. 
This history is mirrored in and facilitated by research activities in universities and public 
research institutes. During the 1990s and 2000s, the Danish government launched several 
strategic research programmes in biotechnology, seeking to foster cooperation between 
universities and industry to turn biotechnology into a strategic asset for the Danish economy 
and society in the future. Significant efforts are also involved in developing a ―Medicon 
Valley‖, a cluster of research and industry in the greater Copenhagen (DK) / Malmö(S) area 
around Øresund. 
While most policy initiatives in this area concentrate on stimulating research and innovation, 
the Danish political system has also devoted attention to the various ethical and socio-
economic controversies, which accompany some of these developments. This has lead to 
the institutionalisation of public debate on biotechnology through such organs as the Danish 
Board of Technology and the Council of Ethics, as well as other more temporary initiatives, 
seeking to stimulated public awareness and debate as well as safeguarding the societal 
legitimacy of these developments. 
The shifting governments (primarily the ministry of science in various configurations) have 
obviously played a strong role in this but, reflecting the Danish tradition of a ―negotiated 
economy‖, most of the policies have be formulated in dialogue with industry and the research 
communities. This applies to all governments over the past 20 years, independently of their 
political ideology. Apart from disagreements about how to handle the issues regarding GM 
food, most of these issues have been managed without significant party political strife. 
In several instances, contentious issues have been delegated to commissions, which were 
broadly constitutes in terms of expertise and societal interests. Among these are the ―BioTIK 
Commission‖ on the ethics of biotechnology, the ―Genetechnology Commission‖ on 
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regulatory needs in regard to four medical biotechnologies (incl. XTP) and the ―Commission 
on Transgenic and Cloned Animals‖. Interviews with different members of these committees 
suggest that apart from some interventions from the responsible ministries to safeguard their 
operational interests, politicians were mostly grateful when commissions could agree on 
quite specific regulatory recommendations, which left little room (or need) for political 
decision making on many of the more (ethically) awkward issues raised by the novel 
biotechnologies. 
8.2.1 Cabinets 
Innovation policy is a major concern for the cabinets, but the more (ethically and socially) 
contentions issues regarding biotechnology has not been an issue for the cabinets. They 
have been dealt with primarily by the bureaucracy, but with the involvement of responsible 
ministers from time to time. 
8.2.2 Legislature 
Biotechnology has been debated on repeated occasions in the Danish parliament. Some 
particularly contentious issues have been dealt with through legislation (cloning, embryonic 
research, release of GMOs etc), but in practice most regulation is delegated to the 
bureaucracy. 
8.2.3 Executive-legislative relationship 
Is not contentious – when disagreements occur, they tend to be articulated between the 
Government and the opposition, not between parliament and the government. 
8.2.4 Bureaucracy 
The bureaucracy runs most of the day-to-day operations in this field. At some point a special 
bureaucratic unit was formed to coordinate biotechnology policies across the government 
(the BioTIK secretariat, see e.g. Hansen 2010), but was dissolved, when the government 
changed in 2001. The relevant ministries are all represented in the commissions described 
above, but mostly play the role as connecting point to the ministries. 
8.2.5 Judicial review 
Courts play virtually no role in this field. There are regulatory oversight of research activities 
through the ―Rådet for Dyreforsøg‖ (chaired by a judge) and the Central committee on 
research ethics (including a lawyer). 
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8.2.6 Party system 
There is no green party in Denmark, as most of the environmental movement‘s issues have 
been appropriated by the existing parties, initially predominantly the two left wing parties, but 
increasing across the political spectrum. While represented in parliament, the Christian 
Democrats found a niche in addressing ethical issues related to biotechnology. The left-wing 
opposition has been critical of GMOs as representing too large risks only to serve agro-
business interests, but in general biotech innovation has not been party political strife. 
Especially in the biomedical domain it is more accurate to say that ethical issues have been 
the source of political confusion and a desire to delegate decisions to advisory bodies such 
as the Council of Ethics and the Genetechnology Commission. 
8.2.7 Interest group system 
In general, interest groups have played a significant role in the biotech policy field. For 
instance, the BioTIK commission was founded in response to the request for regulatory 
clarification from the biotech industry. However, the XTP debates seem to be driven primarily 
by the scientific community and perhaps even more the TA community. Apart from a 
company interested in breeding transgenic pigs for experimental use, there has been no 
commercial interest in this area. Nor has there been any involvement by patients 
association. 
8.2.8 Political culture 
There has been quite a bit of civil society involvement with biotech innovation. Some of 
which has been stimulated through the activities of the Danish Board of Technology, which 
has organised several participatory assessment exercises in regard to biotechnology. As 
part of the ―negotiated economy‖, decision making in this area is thus quite open to inputs 
from outside bureaucratic and expert circles. This, however, does not seem to have applied 
to any significant extend in regard to XTP – or at least the subject does not appear to have 
attracted much attention from outside expert circles. 
8.2.9 Science-society relations 
Some ministries have some in-house expertise on biotechnology, but mostly they rely on 
experts drawn from research institutes and universities. Scientists are often called to serve 
on commissions, where they are joined by civil servants and in some case representatives of 
the business sector and civil society. These commissions work out the state of knowledge in 
a commonly comprehensive language and usually provide recommendations for policy 
decisions (e.g. the BioTIK Commission, the Genetechnology Commission and the 
Commission on Transgenic and Cloned Animals). To a large extent, these recommendations 
are followed by the political system. 
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8.2.10 Direct democracy 
Direct democratic measures have played no role in this domain in Denmark 
8.2.11 Constitutional division of territorial power 
Plays no role in Denmark 
8.3 Social practices in biomedical policy making 
This section contains step by step answers to the questions on social practices posed in the 
―Guidelines Research Methods and Research Questions‖ – some of the answers refer back 
to the case narrative. 
8.3.1 Policy making 
XTP was framed first and foremost as an emerging technology, which was likely to hit 
Denmark from the outside, and for which the regulatory system needed to be prepared. It 
was expected and accepted that Denmark would assume a reactive stance on XTP rather 
than an active, contributing role in the development of the clinical applications. 
As the discussion on XTP gained (a little) momentum in the wake of the controversies on 
GM food and the announcement of Dolly the cloned sheep, XTP was framed as something 
that might potentially raise ethically sensitive issues and possibly generate public concern. 
However, the by far dominant framing in the policy making field had to do with the health 
risks for the general population associated with XTP experimentation. This framing was 
adopted from international discussions on the issue, translated – as far as this research has 
been able to establish – primarily though the activities of the TA community. 
Policy practices included a hearing at the parliament, where interested parliamentarians 
debated with a panel of experts. This was organised by the DBT, which is standard practices 
on issues involving debate about novel technology. Subsequent to this, a debate in 
parliament including questions to and prepared accounts from responsible ministers 
(―forespørgselsdebat‖) was called for by the Christian Democrats. This debate had two 
outcomes: 1) The parliament instructed the responsible minister to ensure that a moratorium 
on XTP was issued. 2) It was agreed that the minister of science should convene a 
committee to scrutinise the problem and if necessary recommend policy revisions. This was 
the ―Genetechnology Commission‖, the terms of reference was subsequently broadened to 
include a range of novel biotechnologies. 
The by far dominant artefact related to this policy process is written reports, which are 
drafted, circulated and translated. 
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The TA activities consisted primarily in two hearings. One exclusively for scientists working 
in the field in order for BioSAM to gather knowledge to inform the policy system and the 
wider public, the other organised for the benefit of parliamentarians. The parliamentary 
hearing was the occasion for the Christian Democrats to bring up the issue in a 
parliamentary debate, which lead to the moratorium being adapted as official policy and the 
formation of the Genetechnology Commission. The Commission in turn assessed that the 
moratorium was a suitable regulatory measure and recommended no further initiatives in 
regard to XTP. 
The Christian Democrat MP interviewed for this inquiry generally praised the DBT as a 
valuable support in the parliamentary work on technological issues, but did not seem to 
differentiate between different kinds of policy advice as TA, PTA or any other categories. 
There was no institutionalised PTA on this matter – but otherwise PTAs are regularly 
organised as part of Danish policy making – although their actual impact is a contested issue 
(e.g. Hansen 2010) 
The resulting policy is a moratorium on all clinical experimentation with XTP. Research on 
cloned and transgenic animals is permitted, but under licensing in regard to animal welfare. 
However, no research is carried out on XTP. 
8.3.2 Citizen Participation 
In the public debate (media coverage) XTP was framed in different ways 
1. as an example of the marvels of modern biotechnology, which could make age-old 
science fictions come true 
2. as a means to remedy the shortage of donor organs 
3. as a potential source of risks to the individual recipients of organs as well as to the 
population at large 
4. as a potential source of ethical concern and disturbance of our image of humanness 
– though this concern was mostly dismissed by utilitarian arguments 
There was practically no involvement of ―ordinary citizens‖ in policy making. Citizens were 
framed as members of the public in need of protection from reckless technological progress. 
Perhaps more surprisingly, nor was there any involvement of patient associations in any of 
the discussions, which would be standard practice in Danish policy making. 
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As there was no citizen participation, it is hard to discern any artefacts involved here – 
perhaps apart from news paper articles. Some newspaper articles carried images relating to 
research or pictures of the transgenic pigs that were designated to be donors. 
Citizens were largely defined as a ―public at risk‖, as potential victims if something should go 
awry in the development process towards clinical application. Citizens were defined as 
―abstract patients‖ that might respond in various (emotional) manners to being confronted 
with the possibility of having an animal organ transplanted into their body. However, not a 
single media report has been found that confronts patients that have actually undergone 
organ transplantation with the idea of transplanting animal organs into human beings. 
8.3.3 TA and PTA 
The following TA tools were used:  
 One-day seminar for invited scientific experts, organised by BioSAM, hosted by the 
University of Copenhagen 
 An expert hearing at the parliament, facilitating discussion between experts and 
parliamentarians 
 The Genetechnology Commission requested to assess if there was a need for 
new/further regulation of the field. 
No PTAs were involved 
The two hearings preceded a parliamentary debate on XTP, and their outcomes fed into the 
parliamentary debate. An outcome of the debate was that the Genetechnology Commission 
was organised. The debate requested a moratorium, and the work of the commission 
suggested to alterations to that. 
The seminar at the University of Copenhagen involved only scientific experts, some from 
abroad. 
The hearing at the parliament involved scientists, ethicists and economists, as well as 
members of the Swedish XTP commission – as well as parliamentarians. 
The Genetechnology commission involved scientists, ethicists, staff from the DBT and civil 
servants, all appointed by the Ministry of Science. 
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Both the seminar and the hearing proceeded by means of experts‘ presentations and 
Questions & Answers sessions with the participants. They were moderated (and 
documented) but did not result in any concrete outputs and decisions. The most material 
outcomes were written resumes and a verbatim transcript from the hearing at the parliament. 
In addition, both events were reported in the newsletter series from BIOSAM. 
The Genetechnology Commission produced a report with an overview of state-of-the-art in 
research written in an accessible language, discussion of various ethical issues and policy 
recommendations. 
The aim of the initial seminar was to create an overview of the field for those involved with 
various aspects, such that BioSAM could present an overview of the field and potentially 
contentious issues to decision-makers and the larger public. 
The aim of the parliamentary hearing was to inform parliamentarians through discussion with 
experts 
The aim of the Genetechnology Commission was to create an overview of the field in terms 
of knowledge, possibilities and challenges to inform public debate and political decision 
making.  
Power asymmetries do not seem to have been an issue that was explicitly reflected upon. 
The ―lay people‖ involved were parliamentarians (which may be lay, but not exactly 
powerless, as the hearing was organised for their benefit). Gender issues do not appear to 
have been a theme at all. 
One peculiarity seems to be the fact that at no point in time was there any attempts made to 
involve patient interests groups. 
No particular problems have been identified  
8.4 Gender issues 
No gender issues are immediately discernable in the XTP debates. The two expert hearing 
organised by BioSAM had a clear male bias in terms of the scientists involved. However, 
there are no indications this has been made a theme in the debates. 
The two commissions discussed in this report (the Genetechnology Commission and the 
Commission on Cloned and Transgenic Animals) both had a more or less equal distribution 
of male and female members. However, it has not been possible to establish whether this is 
coincidental or a deliberate move by the ministry commissioning the work. 
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9 List of Interviewees 
Peter Sandøe, Professor of Bioethics, Chair of the Council of Animal Ethics (13.11.2009) 
Johannes L. Brockdorff, Civil Servant, Secretary to the ―Genetechnology Commission‖ 
(09.12.2009) 
Torben Greve, Professor of Veterinarian Embryology, member of the ―Genetechnology 
Commission‖ (11.12.2009) 
Ebba Nexø, Chair of the ―Genetechnology Commission‖ (08.01.2010) 
Linda Nielsen, Professor of Law, former chair of the Council of Ethics (12.01.2010) 
Anne Lykkeskov, Academic officer at the Council of Ethics (14.01.2010) 
Lene Koch, Historian of Science, former member of the Council of Ethics (26.01.2010) 
Tove Videbæk, former MP, Christian Democrats (12.02.2010) 
Axel Kornerup Hansen, Professor of Veterinary Disease Biology, Chair of the ―Commission 
on Cloned and Transgenic Animals‖ (13.08.2010) 
Sven Gerner Nielsen, Director of ‖Nyreforeningen‖ (Patient organisation for kindney 
transplanted) (17.08.2010) 
Gitte Meyer, Science Journalist, (18.08.2010) 
Berit Faber Nielsen, former chief of secretariat at the Council of Ethics (20.08.2010) 
Lars Klüver, Director, Danish Board of Technology (9.9.2010) 
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10 List of abbreviations 
BIOSAM: Umbrella organization of TA organizations formed to promote TA and public 
debate on biotechnology  
BioTIK: Government initiative to clarify ethical challenges of novel biotechnologies, 
consisting of an expert commission producing a report with ethical principles, which where 
subsequently handed over to an interdepartmental task force commissioned to ensure its 
implementation in legislation as well as stimulating public debate on the ethics of 
biotechnology 
BSE: Bovine spongiform encephalopathy, also known as ―mad cow disease‖ 
CoE: Council of Ethics 
DBT: Danish Board of Technology 
GMO: Genetically modified organisms 
NGO: Non-governmental organisations 
nvCJD: new version Creutzfeld-Jacobs, also known as the human version of ―mad cow 
disease‖ 
TA: Technology Assessment 
XTP: Xenotransplantation 
CIT-PART —Hansen/ Case Study Denmark — 46 
 
11 References 
Allansdottir, Agnes (2010) ―Public view on biotechnology in Eurobarometer Special Surveys‖ 
in Nik Brown and Siân Beynon-Jones (eds) CIT-PART Deliverable 3. Overview on XTP 
policies and related TA/PTA procedures, pp. 125-145 
Bauer, M and Gaskell, G (2002) ―Researching the public sphere of biotechnology‖ in Bauer 
and Gaskell (eds) Biotechnology. The making of a global controversy, Cambridge University 
Press, Cambridge, pp. 1-20 
BIOSAM (1999) ‖Xenotransplantation‖ BIOSAM Informerer, no. 1 
(http://www.biosam.dk/biosam/PDF/Biosam1.pdf) 
BIOSAM (2000) ‖Organgrise – Risici, regler og realisering‖, BIOSAM Informerer, no. 4 
(http://www.biosam.dk/biosam/PDF/Biosam4.pdf) 
BIOSAM (2004) ‖Hvornår flyver grisene? Status på xenotransplantation)‖, BIOSAM 
Informerer, no. 21 (http://www.biosam.dk/biosam/PDF/Biosam21.pdf) 
Cooper, D. et al (1991) Xenotransplation: The transplantation of organs and tissue between 
species, Springer 
Cronberg, T (1995) ―Do marginal voices shape technology‖ in Joss, S and Durant, J (eds) 
Public participation in science. The role of consensus conferences in Europe, Science 
Museum, London, pp. 125-34. 
Danish Board of Technology (2000) Xenotransplantation. Resume og redigeret udskrift af 
intern høring i Folketingen den 23. februar 2000, Teknologirådets rapporter 2000/2, 
København 
Genteknologiudvalget 2002 ‖Fremtidens bioteknologier – muligheder og risici‘‖, Ministeriet 
for Videnskab og Teknologi, København (http://www.fi.dk/publikationer/2002/fremtidens-
bioteknologier-muligheder-og-risici/fremtidens-bioteknologier-muligheder-og-risici.pdf) 
Hansen, J (2010) Biotechnology and public engagement in Europe, Palgrave, Basingstoke.  
Horst, M (2008) ―The laboratory of public debate: Understanding the acceptability of stem 
cell research‖, in Science and Public Policy, Vol. 35, no. 3, pp. 197-205 
CIT-PART —Hansen/ Case Study Denmark— 47 
 
 
Jelsøe, E. et al. (2001) ―Denmark: the revival of national controversy over biotechnology‖, in 
Gaskell. G and Bauer, M (eds) Biotechnology 1996-2000 the years of controversy, Science 
Museum, London, pp. 157-171. 
Joss, S and Durant, J (eds) (1995) Public participation in science. The role of consensus 
conferences in Europe, Science Museum, London. 
Klüver, L (1995) ―Consensus conferences at the Danish Board of Technology‖, in Joss, S 
and Durant, J (eds) Public participation in science. The role of consensus conferences in 
Europe, Science Museum, London. 
Luhmann, N (1991) Die Realität der Massenmedien, Westdeutscher Verlag, Opladen. 
Meyer. G. (1991) Den kunstige krop, Munksgaard, København 
Neidhardt, F. (1993) ―The public as a communication system‖ in Public Understanding of 
Science, Vol. 2, pp. 339-50.  
Pedersen, O. K. (2006) ―Corporatism and beyond: The negotiated economy‖, in Cambell, J, 
Hall, J and Pedersen, O National Identity and the Varieties of Capitalism. The Danish 
experience, Djöf Publishing, Copenhagen, pp 245-270 
Wagner, W. et al (2001) ―Nature in disorder: the troubled public of biotechnology‖, in Gaskel 
& Bauer (eds): Biotechnology 1996-2000 - the years of controversy. Science Museum, pp. 
80-95. 
  
  
  
  
 
 
Author: Janus Hansen 
 
Title: CIT-PART: Report Case Study Denmark 
 
© 2011 Copenhagen Business School 
 
 
